Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · FY 2026

BriaCell Therapeutics FY 2026 Results: Net Loss of $34.9M, Loss Widens

BriaCell Therapeutics Corp. is a pre-revenue clinical-stage biotechnology company facing substantial competition and significant going concern risks. The company expects increased operating expenses as it advances its Phase 3 Bria-IMT™ and Phase 1/2 Bria-OTS™ clinical programs, while managing risks related to data security, key personnel retention, and its majority stake in BriaPro.

FY 2026 at a glance · $ million · annual
MetricFY 2026FY 2025
Net income-34.9-26.3
EPS (diluted, $ a share)$-6.97$-62.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-K filed with the SEC, NASDAQ: BCTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BriaCell Therapeutics Corp.: key numbers

Share price
$3.51Close, Nov 17
Market cap
$30.7M
Shares outstanding
8.73MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.